Neuropathy Less Severe, Frequent With Eribulin vs Paclitaxel
However, among patients with invasive breast cancer, pathologic complete response rates with eribulin were lower. The study was published as a preprint and has not yet been peer reviewed.
First Look
source https://www.medscape.com/viewarticle/968686?src=rss
First Look
source https://www.medscape.com/viewarticle/968686?src=rss
Comments
Post a Comment